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Background: Autism is a neurodevelopmental disorder characterized by impaired language, communication and
social skills. Although genetic studies have been carried out in this field, none of the genes identified have led to
an explanation of the underlying causes. Here, we have investigated molecular alterations by proteomic profiling of
post mortem brain samples from autism patients and controls. The analysis focussed on prefrontal cortex and
cerebellum as previous studies have found that these two brain regions are structurally and functionally connected,
and they have been implicated in autism.
Methods: Post mortem prefrontal cortex and cerebellum samples from autism patients and matched controls were
analysed using selected reaction monitoring mass spectrometry (SRM-MS). The main objective was to identify
significantly altered proteins and biological pathways and to compare these across these two brain regions.
Results: Targeted SRM-MS resulted in identification of altered levels of proteins related to myelination, synaptic vesicle
regulation and energy metabolism. This showed decreased levels of the immature astrocyte marker vimentin in both
brain regions, suggesting a decrease in astrocyte precursor cells. Also, decreased levels of proteins associated with
myelination and increased synaptic and energy-related proteins were found in the prefrontal cortex, indicative of
increased synaptic connectivity. Finally, opposite directional changes were found for myelination and synaptic proteins
in the cerebellum.
Conclusion: These findings suggest altered structural and/or functional connectivity in the prefrontal cortex and
cerebellum in autism patients, as shown by opposite effects on proteins involved in myelination and synaptic function.
Further investigation of these findings could help to increase our understanding of the mechanisms underlying autism
relating to brain connectivity, with the ultimate aim of facilitating novel therapeutic approaches.
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Autism spectrum disorders (ASDs) are neurodevelop-
mental conditions characterized by impairments or alter-
ations in socialisation, with language changes and
restricted and/or repetitive behaviours. Recent studies
have estimated the prevalence of autism at 1 in 110 with
evidence for a strong gender bias. Approximately four
times as many males as females are diagnosed with aut-
ism based on Diagnostic and Statistical Manual of Men-
tal Disorders (DSM)-5 criteria. Children with autism
commonly display abnormal development before the age
of three years, particularly those with the regressive aut-
ism sub-type [1-3]. Despite the distressing effects that
autism can have on the lives of patients and their fam-
ilies, the molecular basis of this condition remains
largely unknown. Consequently, there are still no effect-
ive pharmacological interventions that can ameliorate
the core symptoms of autism.
A number of previous studies have attempted to eluci-
date pathomechanisms associated with autism using
imaging, genetic and transcriptomic approaches. Al-
though results have been sparse and sometimes conflict-
ing across studies, a consensus has emerged which
suggests changes in brain connectivity and synaptic
function in autism patients [1,4]. Specific genes which
have been implicated include NLGN1 (neuroligin) and
NRXN1 (neurexin) [4], and this has suggested that
changes in local and distal connectivity may result from
an imbalance of neuronal excitation and inhibition [5,6].
This may also involve dysfunction of myelination
pathways, as shown by the finding of circulating
antibodies against myelin basic protein (MBP) and
myelin-associated glycoprotein (MAG) in some autism
patients [7,8].
Proteomic profiling studies have shown that brain-
derived neurotrophic factor (BDNF) and glial fibrillary
acidic protein (GFAP) are altered in autism patients.
BDNF is a growth factor which may be related to the in-
creased brain volumes seen in some young children with
autism [9]. This is consistent with the findings of im-
aging studies of autism subjects, which have identified
aberrant white matter growth patterns [10-12]. GFAP is
an astrocytic marker and astrocytes are known to be in-
volved in synaptic connectivity and inflammation [13].
Increased astrocyte activity has been observed in ASD
patients [14,15] and changes in inflammatory pathways
have been observed in the cerebral cortex, white matter
and cerebellum [16]. Furthermore, circulating autoanti-
bodies have been detected against GFAP and other pro-
teins involved in neuronal and synaptic functions,
including neurotrophic factors and neuronal-axonal fila-
ments [17,18]. Finally, changes in mitochondrial and en-
ergy pathways have also been reported [19], although it
has been hypothesized that these changes may besecondary to an as yet unidentified disease process [20].
Several independent studies have corroborated that cre-
atine kinase (CK), an enzyme important for energy
homeostasis, is one of the most robust chemical changes
in autism and this is likely to parallel changes in synaptic
remodelling [21].
In order to extend these studies and increase our under-
standing of the proteins and biological pathways affected
in autism, we have carried out a targeted proteomic profil-
ing study of post mortem brain samples from individuals
with autism compared to controls, using selected reaction
monitoring mass spectrometry (SRM-MS). SRM is an ac-
curate, reproducible and quantitative technique to meas-
ure predetermined sets of proteins within the femto- to
attomolar concentration range [22,23]. This method has
advantages over Western blot analysis as multiple readings
are taken of each analyte compared to only one for West-
ern blot analysis [24]. Furthermore, the targeting of pep-
tide sequences analyzed in the SRM method makes this a
highly specific and quantitative analytical method whereas
the Western blot approach relies on antibody reactivity
and, therefore, may result in non-specificity due to poten-
tial antibody cross reactivity [25]. Our main objective was
to identify changes in protein expression levels and to ex-
plore whether the affected proteins could be associated
with the dysconnectivity hypothesis of autism.
Methods
Subjects
Post mortem prefrontal cortex (PFC) (Brodmann area 10;
autism n = 10, controls n = 10) and cerebellum (CB) (lat-
eral posterior and anterior lobe, autism n = 16, controls
n = 17) were provided by the National Institute of Child
Health and Human Development (NICHD) Brain and Tis-
sue Bank for Developmental Disorders (University of
Maryland School of Medicine, Baltimore, MD, USA). Pa-
tients were matched to controls with respect to age of
death (PFC: P = 0.99; CB: P = 0.80), gender (PFC: P = 1.00;
CB: P = 0.70), post mortem interval (PMI) (PFC: P = 0.08;
CB: P = 0.18) and brain pH (PFC: P = 0.51; CB: P = 0.66),
which is indicated in the additional files (see Additional
file 1 for PFC and Additional file 2 for CB). The analysis
of prefrontal cortex included samples from 10 autism indi-
viduals (age = 21.3 ± 4.3 years, PMI = 22.1 ± 3.9 hours) and
10 matched controls (age = 21.4 ± 4.3 years, PMI = 14.7 ±
0.8 hours), and cerebellum tissue included 14 individuals
with a diagnosis of autism (age = 18.6 ± 3.4 years, PMI =
22.7 ± 3.5 hours) and 17 matched controls (age =17.5 ±
2.9 years, PMI = 16.7 ± 1.6 hours) (Table 1). The study was
approved by the Columbia University Medical School
Institutional review board, consent was obtained from
next of kin and all samples were de-identified and per-
sonal information anonymised. Diagnosis of autism was
confirmed by the structured Autism Diagnostic Interview-
Table 1 Demographic data for control and autism subjects
Diagnosis Gender Age PMI (hours) Ethnicity Medication history Brain area
control male 12 16 Caucasian NA CB
control male 20 18 Caucasian NA PFC
control male 37 12 African American marijuana PFC, CB
control male 9 36 Caucasian NA CB
control female 19 29 Caucasian none CB
control female 20 9 Caucasian none CB
control male 46 13 Caucasian NA PFC, CB
control male 5 18 African American NA CB
control male 8 16 African American NA PFC, CB
control male 20 19 Caucasian NA CB
control female 4 15 African American NA CB
control male 22 13 African American none PFC, CB
control female 16 13 Caucasian NA PFC, CB
control male 33 16 Caucasian NA PFC, CB
control male 15 12 Caucasian NA CB
control female 16 11 Caucasian NA PFC, CB
control male 13 19 Caucasian NA PFC, CB
control male 3 16 Hispanic none PFC, CB
autism female 20 50 Caucasian NA CB
autism, MR male 9 12 African American Zyprexa, Reminyl CB
autism, S male 11 27 Hispanic NA PFC, CB
autism female 4 13 African American NA CB
autism male 9 16 African American NA CB
autisma male 7 20 African American NA CB
autism male 14 9 Caucasian NA CB
autism, MR male 20 14 Caucasian Naltrexone PFC, CB
autism male 38 26 African American Respirdal, Luvox PFC, CB
autism, S male 46 29 Caucasian NA PFC, CB
autism male 7 3 Caucasian NA PFC
autism male 22 18 African American Risperdal PFC, CB
autism, S female 16 13 Caucasian Depakote, Keppra, Vitamin B6 and Prozac PFC, CB
autism, MR male 33 50 Caucasian Seroquel, Prozac, Depakote, Geodon PFC, CB
autism, S male 16 20 Caucasian Risperdal, Luvox, Clonidine and Insulin PFC, CB
autism male 4 21 Caucasian NA PFC, CB
ID = identification code, PFC = prefrontal cortex, CB = cerebellum, MR =mental retardation, S = seizure, NA = Not Applicable for control subjects and Not Available
for cases. aThis sample was removed as an outlier and not considered in further statistical analyses.
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hood autism rating scale (CARS), family history documen-
tation, gene analysis to exclude genetic disorders and
mutations, and neurological examination (Table 1). Sub-
jects with a diagnosis of autism were included in the
study. Local ethical approval for use of this tissue was
granted by the Cambridgeshire Local Research Ethics
Committee.Sample preparation
All biochemicals and reagents were obtained from Sigma-
Aldrich (Poole, UK) unless specified otherwise. Brain tis-
sues (approximately 30 mg) were sectioned using a Leica
Cryostat (Milton Keynes, UK), collected into pre-chilled
lysing matrix D tubes (MP Biomedicals; Cambridge, UK)
and stored at −80°C until use. Protein extraction was per-
formed by addition of fractionation buffer (7 M urea, 2 M
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1-propanesulfonate, 2% ASB14 and 70 mM dithiotreitol
(DTT), followed by sonication for 10 seconds using a
Branson Sonifier 150 (Thistle Scientific; Glasgow, UK)
and vortexing for 30 minutes at 4°C. The homogenates
were centrifuged for 3 minutes at 17,000 g and the super-
natants collected for precipitation of the proteins using
4:1 volumes ice-cold acetone. The resulting pellets were
suspended in 100 μL of 50 mM NH4HCO3 (pH 8.0). Sulf-
hydryl groups on proteins were reduced by incubation
with 100 mM DTT for 30 minutes at 60°C and alkylated
with 200 mM iodacetamide for 30 minutes at 37°C. Pro-
teins were cleaved into peptides by incubation with 1:50
(trypsin:protein) porcine trypsin (Promega; Madison, WI,
USA) for 17 hours at 37°C and stopped after 16 hours by
addition of 0.80 μL of 8.8 M HCl. Samples were stored
at −80°C. Prior to mass spectrometry analyses, 0.1% for-
mic acid was added to a final concentration of 0.12 μg/μL
protein.
SRM-MS
Digested prefrontal cortex and cerebellum proteomes
were analysed using SRM-MS on a Xevo TQ-S mass spec-
trometer coupled to a nanoAcquity UPLC system (Waters
Corporation, Wilmslow, UK), as described previously [23].
Protein candidates were selected for this analysis given
their association with pathways which have been impli-
cated previously in autism. Physiochemical criteria for
selecting tryptic peptides were based on peptide count,
uniqueness and quality of transitions. All SRM functions
had a 6 minute window of the predicted retention time
and scan times were 0.02 seconds. Two peptides were se-
lected for each target protein and isotopically-labelled
peptides were synthesized at JPT Peptide Technologies
GmbH (Berlin, Germany). The samples and labelled pep-
tides were mixed together and separated using the follow-
ing 42 minutes gradient: 97/3% (A/B) to 70/30% in
20 minutes; 70/30% to 15/85% in 5 minutes; and in 3 mi-
nutes to 97/3%. Peptide spectra were acquired in SRM
mode using a capillary voltage of 2.35 kV and a cone volt-
age of 33 V. At least three transitions were measured for
each peptide. The candidate proteins were identified with
the SRM method as described previously [23].
Statistical analyses
Statistical analyses of SRM data were conducted in the R
statistical programming language (version 2.15.3; www.r-
project.org), using the package MSstats [26-28]. Data pro-
cessing consisted of log2 transformation to stabilize the
variance and normalize peak intensities. The data were
then analysed using a linear mixed model to detect pro-
teins or peptides that were present at significantly differ-
ent levels in cases compared to controls (autism/control).
In the model, the experimental characteristics were linkedto the data in terms of biological condition, labelling state,
technical and biological replication and potentially inter-
fering transitions [28]. The scope of inference for both
biological replicates and technical replicates were set to
‘restricted’, as conclusions about the data are confined to
the study itself. Furthermore, additional model interac-
tions were performed for interference transitions. These
analyses resulted in P-values, Q-values (allowing for mul-
tiple testing) and ratio changes (autism/control).
Results
Sample quality
SRM-MS analysis of prefrontal cortex protein extracts
from autism and control patients showed no batch ef-
fects as indicated by principal component analysis
(PCA), of which an additional plot shows this in more
detail (Additional file 3). Conversely, analysis of the cere-
bellum protein extracts led to the identification of one
outlying sample. After removal of this sample, no further
outliers were detected, as is visualised in the additional
PCA plot (Additional file 4). All further statistical ana-
lyses were carried out using only the remaining samples.
SRM-MS detection
SRM-MS was used for targeted analysis of proteins associ-
ated with energy metabolism, astrocyte function, myelin-
ation and synaptic vesicles in accordance with literature
evidence [4-21]. The proteins which were detectable using
SRM-MS analysis are indicated in Table 2. GFAP, vimentin
(VIME), creatine kinase B-type (CKB), MAG, MBP, myelin-
oligodendrocyte glycoprotein (MOG), myelin proteolipid
protein (PLP1), dynamin-2 (DNM2), syntaxin-1A (STX1A),
syntaxin-binding protein 1 (STXBP1), synapsin-2 (SYN2),
synaptotagmin-1 (SYT1), protein kinase C casein kinase
substrate 1 (PACSIN1) were detected in both prefrontal
cortex and cerebellum from all patients and controls. How-
ever, reelin (RLN) was only identified in the cerebellum and
was therefore not used in the comparative analysis.
Comparative SRM-MS analysis of proteins in prefrontal
cortex and cerebellum
Prefrontal cortex and cerebellum showed a similar decrease
in the levels of the immature astrocyte marker VIME,
whereas the mature astrocyte marker GFAP was increased
and this occurred only in the cerebellum (Figure 1). The
energy-related CKB was increased by more than 70% in the
prefrontal cortex and showed a non-significant decrease
(P = 0.2605) in the cerebellum. The myelin-related proteins
MAG and PLP1 were decreased in the prefrontal cortex
with a concomitant increase in the synaptic proteins SYN2
and STBP1, although the latter was not significant (P =
0.1002). Conversely, the myelin related proteins MAG,
MBP, MOG and PLP1 were all increased by more than 30%
and the synaptic proteins STX1, SYT1 and PACSIN1 were
Table 2 SRM-MS testing of targeted candidate proteins in post mortem prefrontal cortex and cerebellum from autism
patients compared to matched controls
Prefrontal
cortex
Cerebellum Prefrontal
cortex
Pathways Gene Protein name ratio P-value Pathways Gene Protein
name
ratio
Cell adhesion RELN Reelin ND ND Cell adhesion RELN Reelin ND
Astrocyte GFAP Glial fibrillary acidic protein 1.02 0.7399 0.7968 1.14 1.8E-05a 7.42E-5
VIME Vimentin 0.69 2.8E-5a 0.0002 0.56 1 < E-10a 1 < E-9
Energy CKB Creatine kinase B-type 1.73 1.3E-9a 1.82E-8 0.92 0.2605 0.3777
Myelin MAG Myelin-associated glycoprotein 0.76 0.0087a 0.0272 1.30 0.0016a 0.0042
MBP Myelin basic protein 0.85 0.1440 0.2373 1.41 0.0003a 0.0009
MOG Myelin-oligodendrocyte glycoprotein 0.81 0.0567 0.1222 1.37 0.0002a 0.0006
PLP1 Myelin proteolipid protein 0.82 0.0143a 0.0400 1.37 2.8E-10a 2.69E-9
Synaptic vesicle DNM2 Dynamin-2 1.05 0.7811 0.8024 0.87 0.2910 0.4018
STX1A Syntaxin-1A 1.07 0.2086 0.3165 0.88 0.0102a 0.0227
STXBP1 Syntaxin-binding protein 1 1.28 0.1002 0.1753 0.97 0.8031 0.8626
SYN2 Synapsin-2 1.29 0.0486a 0.1135 1.04 0.6499 0.7539
SYT1 Synaptotagmin-1 1.06 0.4092 0.5456 0.87 0.0165a 0.0342
PACSIN1 Protein kinase C casein kinase substrate 1 0.96 0.4540 0.5778 0.84 8.1E-5a 0.0003
ND = not detected; asignificant P-value.
Indicated are the themes, protein name, the ratio (autism/control), the P-value and the Q-value. Grey shading indicates the proteins with a significant P-value or
Q-value and a ratio of >10%.
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the cerebellum although this was not significant (P =
0.2910).
Discussion
This is the first report presenting results from a proteo-
mics mass spectrometry study of rare post mortem brain
tissues from autism patients and controls. Prefrontal cor-
tex and cerebellum proteomes were investigated because aFigure 1 Histogram showing selected reaction monitoring mass spec
maturation, energy production, axon myelination and synaptic vesicl
mortem prefrontal cortex (black) and cerebellum (grey) tissues from autism
defined in Table 2.number of studies have already shown that these brain re-
gions are affected in autism [29-32]. It has previously been
suggested that impaired prefrontal cortex-cerebellar cir-
cuitry may be linked to autism symptoms [33]. In addition
to its well known role in regulation of motor functions, it
is now established that the cerebellum is also involved in
regulation of cognition and other higher brain functions.
Structural studies in non-human primates have shown
that the cerebellum receives inputs through afferenttrometry (SRM-MS) analysis of proteins involved in astrocyte
e release. The percent changes of each protein are shown for post
patients compared to matched controls. The protein codes are
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tex which are known for their role in cognition and mood
regulation [34-36]. Likewise, efferent nerves from the
cerebellum have been traced to both motor and non-
motor areas of the frontal cortex [37,38], which are routed
through thalamic nuclei and complete the circuit [38].
Furthermore, functional evidence for a role of the cerebel-
lum in higher brain function has been demonstrated by
magnetic resonance imaging (MRI), which showed that
activity in the cerebellar dentate nucleus correlated with
changes in activity in the limbic system, parietal lobes and
prefrontal cortex [39].
The main findings of this study provide evidence that
molecular processes are differentially dysregulated in dif-
ferent brain regions in autism, which could affect various
higher functions such as cognition, working memory,
mood and emotions [40-42]. Here, the SRM-MS results
showed decreased levels of proteins associated with
myelination and increased levels of synaptic proteins in
the prefrontal cortex, with opposite directional changes
of the same proteins in the cerebellum. This is consist-
ent with our unpublished observations showing de-
creased levels of myelin proteins in post mortem
prefrontal cortex tissue in other psychiatric disorders,
such as schizophrenia, bipolar and major depressive dis-
order. Furthermore, dysregulation of synaptic proteins
may reflect alterations in synaptic density and a com-
parison with published data confirms the alterations of
STX1A, STXBP1 and SYN2 in autism at the mRNA
level [43]. In addition, SRM-MS showed an approximate
70% increase in the levels of CKB in the prefrontal cor-
tex with a small non-significant decrease of this protein
in the cerebellum. CKB has been used as an indicator of
functional activation in magnetic resonance spectros-
copy studies of the brain [44]. Increased myelination has
an important role in promoting and maintaining axon
integrity by increasing axonal calibre and thereby pre-
venting sprouting and synaptic plasticity [45]. Moreover,
decreased myelin thickness has previously been associated
with disconnection of long-distance pathways, neighbour-
ing connectivity and disruption of pathways involved in
emotions [46]. Therefore, the current findings could
suggest differential regulation of local synaptic connectiv-
ity in the prefrontal cortex and the cerebellum of autism
patients.
It is possible that changes in local connectivity impair
the transfer of information across different brain regions,
given that the higher brain functions mentioned above
require co-activation of networked brain areas [31]. Ac-
tivation is known to be coordinated based on inter-
regional relaying of signals through the connecting white
matter tracts [47] and previous studies in autism have
found changes in connectivity and overgrowth of brain
tissues [40], along with alterations of white matter[6,48]. However, studies have shown that the patterns of
white matter aberrations tend to differ depending on
brain area, age and research techniques [6,40,48]. There-
fore it is interesting that the present findings identified a
difference in myelination-related protein levels in the
prefrontal cortex and cerebellum. As white matter is
mainly comprised of glial cells and myelinated axons,
the current changes in myelin-related proteins may be
associated with the proposed disconnectivity in autism.
Likewise, we also identified decreased levels of the im-
mature glial cell marker VIME in both brain regions and
increased levels of GFAP in the cerebellum. This may be
indicative of a relative loss of astrocyte precursor cells in
the cerebellum of autism patients.
Cerebellar damage can result in verbal and communi-
cation deficits, as well as a reduction of higher-order ex-
ecutive functions and other cognitive abilities such as
language processing, visuospatial abilities and attention
[49]. Dysfunction of these pathways could be due to loss
of cerebellar Purkinje cells, which has been observed in
post mortem brains from autism patients compared to
controls. Interestingly, this does not appear to be related
to seizure activity as patients both with and without co-
morbid epilepsy showed Purkinje cell loss [50,51].
One limitation of the present investigation was the
low statistical power for detection of proteomic changes.
This resulted from the limited number of post mortem
samples available and the relatively wide age ranges of
the subjects. However, the low numbers could not be
avoided due to the scarcity of such high quality samples
in brain banks. Moreover, the number of samples from
female subjects is low due to the lower female preva-
lence [52]. Also, the different age groups studied could
result in a masking of some molecular changes since
previous studies have shown age dependent changes in
the levels of many serum proteins in children and ado-
lescents with autism [53]. Due to the rarity of these sam-
ples, the subjects were matched only for gender and age
but not for drug treatment. Therefore, we cannot rule
out the possibility that some of the changes may be
medication or drug effects. Therefore, the presented
findings should be considered preliminary and further
validation studies should be carried out using larger
sample sets, once these become available. This will re-
quire increased bio-banking efforts to allow studies in-
volving stratification of samples by age and gender.
Conclusion
The findings from our proteomics study suggest brain
region-specific changes in local connectivity in the pre-
frontal cortex and cerebellum in autism patients as
shown by opposite regulation of proteins involved in
myelination and synaptic regulation. These effects ap-
peared to be associated with differential effects on glial
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lease across the two brain regions. Further molecular
profiling and imaging studies on a larger brain sample
set is required to increase our understanding of the mo-
lecular pathologies of autism and for validation of the
current findings. Once more brain samples are available,
it will be particularly important to undertake studies on
a larger sample set to investigate gender and age-related
changes in autism. Such more detailed and refined in-
vestigations should lead to further insights into the path-
ways affected in autism with the aim to increase our
understanding of this debilitating disorder and facilitate
the development of novel therapeutic approaches.
Additional files
Additional file 1: Demographic information for cohort of which the
prefrontal cortex was analyzed.
Additional file 2: Demographic information for cohort of which the
cerebellum was analyzed.
Additional file 3: Principal component analysis (PCA) plots of
SRM-MS data obtained from prefrontal cortex. In the PCA plots, every
run is represented as a data point and all triplicates of the same run have
the same colour. Samples of both controls and patients are visualised. No
segregation of samples was identified, indicating that a batch effect was
not present. The accompanying text with the data points is not similar to
the sample code depicted in Table 1.
Additional file 4: Principal component analysis (PCA) plots of
SRM-MS data obtained from the cerebellum. In the PCA plots, every
run is represented as a data point and all triplicates of the same run have
the same colour. Samples of both controls and patients are visualised.
After removal of one outlier, the PCA plot showed no segregation of
samples, indicating that a batch effect was not present. The
accompanying text with the data points is not similar to the sample
code depicted in Table 1.
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